Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as latest therapeutics for areas of high unmet medical need, has signed an exclusive license with the University of Southern Denmark for its UbiSite® technology.
UbiSite will form a latest component in Ubiquigent’s DUB and ubiquitin-proteasome system (UPS) focused drug discovery platform, providing a totally supported ubiquitomics service to facilitate goal identification, goal validation, and compound mechanism of motion.
UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture and further identification of protein ubiquitylation sites in cell and tissue samples, enabling a more detailed evaluation to disclose deeper insights into the ubiquitome. The validated, ready-to-use service can distinguish between ubiquitin and ubiquitin-like modifications, resembling SUMO, Nedd8, and ISG15 on lysine residues, in addition to on serine and threonine residues which have only recently been identified.
We’re delighted to have acquired an exclusive license agreement for the UbiSite technology. UbiSite provides a further layer to Ubiquigent’s drug discovery and development capabilities, allowing us to completely support our customers with a validated ubiquitomics service that allows deeper insights into the ubiquitome, in addition to to strengthen the event of our own portfolio of novel DUB modulators and associated drug discovery programmes.
Dr. Sheelagh Frame, Chief Scientific Officer, Ubiquigent
DUBs regulate ubiquitylation, key to cellular protein homeostasis, activity, and degradation, and thereby hold huge potential as exciting latest drug discovery targets. We’re pleased to be licensing our UbiSite technology to Ubiquigent, a Company that’s strongly positioned to facilitate DUB focused drug discovery programmes and power advances on this largely unexploited field.
Professor Blagoy Blagoev, Academic Inventor of UbiSite Technology, University of Southern Denmark
Using the UbiSite technology in a vital collaborative research project, my lab has been capable of obtain ubiquitomics data that we had previously been unable to attain with alternative methods. UbiSite shall be an awesome asset to Ubiquigent’s end-to-end drug discovery platform, further extending the reach of the Company’s services and capabilities.
Professor Sir Philip Cohen, Chair of the Scientific Advisory Board, Ubiquigent